Company: HCTI
Filing Date: 2025-10-16
Form Type: S-3
Source: 0001213900-25-099533
Chunk: 23

Company: Healthcare Triangle, Inc.
Filing Date: 2025-10-16
Form: S-3
Chunk 23
---
 or the perception that these sales might occur, could depress the market price of our Common Stock and could impair our
ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may have
on the prevailing market price of our shares.

We have financed our operations, and we expect
to continue to finance our operations, acquisitions, if any, and the development of strategic relationships by issuing equity, warrants
and/or convertible securities, which could significantly reduce the percentage ownership of our existing stockholders. Further, any additional
financing that we secure may require the granting of rights, preferences or privileges senior to, or pari passu with,
those of Common Stock. Additionally, we may acquire other technologies or finance strategic alliances by issuing our equity or equity-linked
securities, which may result in additional dilution. Any issuances by us of equity securities may be at or below the prevailing market
price of our Common Stock and in any event may have a dilutive impact on your ownership interest, which could cause the market price of
our Common Stock to decline. We may also raise additional funds through the incurrence of debt or the issuance or sale of other securities
or instruments senior to our shares of Common Stock. The holders of any securities or instruments we may issue may have rights superior
to the rights of our holders of our Common Stock. If we experience dilution from issuance of additional securities and we grant superior
rights to new securities over common stockholders, it may negatively impact the trading price of our shares of Common Stock.

For more information about our SEC filings, please
see “Where You Can Find More Information” and “Incorporation by Reference.”

Additional risks not presently known or that we
presently consider to be immaterial could subsequently materially and adversely affect our financial condition, results of operations,
business, and prospects.

<div align='center'>12

WARRANT INDUCEMENT PRIVATE PLACEMENT</div>

On October 2, 2025, we entered into the Inducement
Agreement with the Warrant Inducement Holders that had previously purchased warrants to purchase shares of Common Stock originally issued
in a private placement offering that closed on February 28, 2025, with a current exercise price of $ 20.916 per share (the “Existing
Warrants”). Pursuant to the Inducement Agreement, the Warrant Inducement Holders agreed to exercise in cash the Existing Warrants
at a reduced exercise price of